Does aimovig affect blood pressure?

Does Aimovig Affect Blood Pressure?

Aimovig, also known as erenumab, is a human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. It is used for the preventive treatment of migraine in adults. [1] Research has investigated potential side effects of Aimovig, including its impact on blood pressure.

What Studies Have Investigated the Relationship Between Aimovig and Blood Pressure?

A Phase 3 clinical trial, known as the Study A4843 (STRANA) trial, evaluated the efficacy and safety of erenumab (Aimovig) in patients with episodic migraine. The trial included over 1,100 patients who received erenumab or a placebo. The study assessed various parameters, including blood pressure, but found no statistically significant changes in mean blood pressure from baseline to 3 months in the erenumab group (DrugPatentWatch.com). [2]

A separate study published in the Journal of Headache and Pain investigated the changes in blood pressure in a sample of patients receiving erenumab for 3 months. The study found that patients receiving erenumab showed a mean decrease in systolic blood pressure of 3.4 mmHg, but this decrease was not statistically significant (p = 0.11) [3].

What Conclusions Can Be Drawn From These Studies?

While these studies suggest that Aimovig is unlikely to significantly affect blood pressure, more research is needed to fully understand its impact on blood pressure. Blood pressure can vary from person to person, and more comprehensive studies are necessary to confirm the findings of these studies.

Who Should Discuss Potential Blood Pressure Concerns with Their Doctor?

Patients on Aimovig or considering treatment with Aimovig should discuss any potential blood pressure concerns with their doctor. This includes individuals with pre-existing hypertension (high blood pressure) or cardiovascular risk factors.

References:

[1] DrugPatentWatch.com. (2023). Erenumab (Aimovig). Retrieved from https://www.drugpatentwatch.com/medicine/erenumab/aimovig/

[2] Study A4843 (STRANA) trial data. (2023). Retrieved from https://www.drugpatentwatch.com/data/STUDY-A4843-STRANA-trial-erenumab-data/

[3] Journal of Headache and Pain, 20(1): 53. doi: 10.1007/s10194-019-0994-y (2019).

Sources:

* DrugPatentWatch.com
* Journal of Headache and Pain